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Recent studies have shown that not only plasma brain natriuretic peptide 
(BNP)-32, but also plasma proBNP-108 are increased in heart failure (HF) and 
that current BNP-32 assay kit crossreacts proBNP-108. We also showed that both 
BNP-32 and proBNP-108 were higher in HF than in normal. The 
proBNP-108/total BNP (BNP-32+proBNP-108) ratio was widely distributed and 
HF with ventricular overload had higher proBNP-108/ total BNP ratio than HF 
with atrial overload. Consistent with this finding, proBNP-108 was the major 
molecular form in ventricular tissue, and BNP-32 was the major molecular form 
in atrial tissue. In addition, proBNP-108 was the major molecular form of BNP in 
pericardial fluid. The proBNP-108/total BNP ratio increased with deterioration of 
HF and decreased with improvement of HF. Thus, not only BNP-32, but also 
proBNP-108 is increased in HF and the proBNP/total BNP ratio also rises in 
association with pathophysiological conditions such as ventricular overload. A 
new hypothesis that O-glycosylation at Thr-71 in a region close to the cleavage 
site impairs proBNP-108 processing was proposed. In the future, the precise 








































































       Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) is a 
cardiac hormone and a member of the natriuretic family. (1) Both ANP and BNP 
preferentially bind to natriuretic receptors-A (NPR-A), whereas C-type natriuretic 
peptide (CNP) specifically binds to NPR-B. The most abundantly expressed in 
the heart are ANP and BNP, and they are mainly secreted from the cardiac atrium 
and ventricle, respectively. ANP and BNP play an important role in the regulation 
of blood pressure and body fluid homeostasis. In addition these peptides have 
pleiotropic effects, because NPR-A is widely distributed throughout the body 
(e.g., in the kidneys, vessels, adrenal glands, central nervous system, bone, 
adipocytes, and heart). 
    BNP has a strikingly similar to ANP with regard to both its amino acid 
sequence and its pharmacologic profile (2). Stress to the ventricle such as pressure 
overload, volume overload, myocardial ischemia, neurohumoral factor and 
cytokine stimulate BNP gene expression, and proBNP[1-108] (proBNP-108) is 
produced (3,4,5). Thus, plasma BNP is increased in heart failure and it has been 
used as a useful biochemical marker for heart failure. When proBNP-108 is 
secreted from the ventricular myocyte (4,5), it has been thought to be cleaved to 
proBNP[77-108] (BNP-32) and N-terminal proBNP[1-76] (NT-proBNP-76) in an 
equimolar fashion by furin, corin or other currently unknown proteases. However, 
recent studies have shown that not only BNP-32 and NT-proBNP-76, but also 
proBNP-108 circulates in human plasma and that the proBNP-108level is also 
increased in heart failure (6,7,8). Other studies have found that the present assay 
kit for BNP-32 recognizes proBNP-108 at high cross-reactivity in addition to 
authentic BNP-32 (9,10).  
       However, the reason why proBNP-108 is secreted without specific 
conversion into BNP-32 and NT-proBNP-76 remains unknown. The proBNP-108 
levels and relative ratio of proBNP-108 to BNP-32 in plasma from patients with 



































































recently reported to be heavily O-glycosylated in its N-terminal peptide (11,12). 
Thus, it is considered to be important to examine the ratio of proBNP-108 to 
BNP-32 in the plasma and its relation to pathophysiological conditions of the 
patients with heart failure. 
       We review the current status of BNP studies regarding its molecular forms 
and pathophysiology of heart failure, primarily based on our recent report (13). 
 
Method for the measurement of the proBNP/total BNP ratio in normal and 
heart failure 
First, we compared plasma BNP-32 and proBNP-108 levels in control 
subjects, patients with lone atrial fibrillation, and patients with heart failure. 
Blood samples (3 mL) were withdrawn from all subjects via the antecubital vein. 
Blood was immediately transferred into chilled glass tube containing disodium 
EDTA (1 mg/mL) and aprotinin (500 U/mL). Blood was centrifuged immediately 
at 4°C and the plasma was frozen and stored at -80° C. Plasma sample was 
extracted with Sep-Pak C18 cartridges (Waters, Milford, MA, USA) as previously 
reported method (13). The eluate was lyophilized and dissolved in 30% 
acetonitrile containing 0.1% TFA. An aliquot of the solution was subjected to gel 
filtration high performance liquid chromatography (HPLC) on a TSK gel 
G2000SWXL column (7.8 x 300 mm, Tosoh) as previously reported (13). Each 
fraction was measured by immunofluorescent BNP assay kit (TOSO, Japan). 
ProBNP-108/total BNP ratio was calculated based on the summation of a high 
molecular weight (MW) immunoreactive (IR-) proBNP-108 and a low MW 
IR-BNP-32 with the following formula: proBNP-108/total BNP ratio = 
IR-proBNP-108/(IR-proBNP-108+IR-BNP-32). 
Since very recent studies have revealed that glycosylated pro-BNP of MW 
about 35K is circulating in plasma (11,12), we examined their elution positions of 
recombinant proBNP-108 (HyTest, Finland), glycosylated proBNP-108 (HyTest, 



































































evaluate the cross-reactivity of proBNP-108 and glycosylated proBNP-108 in the 
immunofluorescent assay (FIA) kit for BNP-32, an aliquot of each peptide was 
subjected to acid hydrolysis at 110C for 22 h to estimate peptide contents by 
amino acid analysis (L-8500 analyzer, Hitachi, Tokyo, Japan), and another aliquot 
was submitted to the FIA for BNP-32, after desalting purchased peptides. In this 
system, we were able to accurately evaluate the proBNP/total BNP ratio because 
we used one assay system almost equivalently recognizing BNP-32 and 
proBNP-108. Some studies evaluated the proBNP/total BNP ratio by using a 
distinct assay system for proBNP or BNP-32. In such a study, different affinities 
of antibodies against proBNP, BNP-32 and their related peptides in each system 
hamper accurate evaluation of the proBNP/total BNP ratio.  
 
Plasma concentrations of IR-BNP-32, IR-proBNP-108 and proBNP/total 
BNP ratios in control, atrial fibrillation, and heart failure. 
           As shown in Figures 1-A and 1-B, two peaks of IR-BNP were constantly 
observed in all cases. The first peak was observed in fractions #9-16 of MW larger 
than 13K, and the second peak was in fractions #18-21 of MW 3.5K 
corresponding to BNP-32. In this gel filtration HPLC, recombinant proBNP-108 
and glycosylated proBNP-108 were eluated mainly in fraction #14 and fraction 
#15, being not separable of glycosylated proBNP-108 and non-glycosylated 
proBNP-108 with each other. In the following part the term IR-proBNP-108 
indicates high MW IR-BNP, which includes both proBNP-108 and glycosylated 
proBNP-108, while IR-BNP-32 indicates low MW IR-BNP that is mainly 
composed of BNP-32. The proBNP-108/total BNP ratio was narrowly distributed 
in control and atrial fibrillation; however, the proBNP-108/total BNP ratio was 
widely distributed in patients with heart failure (Figure 1-C). Thus, the mean 
proBNP-108/total BNP ratio in heart failure was significantly lower in heart 
failure than in control or atrial fibrillation.  



































































proBNP-76 in an equimolar fashion by a processing enzyme, when proBNP-108 
is secreted from the ventricular myocyte (1,5). However, recent studies have 
shown that not only BNP-32, but also proBNP-108 circulates in human plasma 
and they are increased in patients with heart failure (7-9). However, there were 
few studies, which measured both BNP-32 and proBNP-108 using the same assay 
kit. From these results, we confirmed that high and low MW forms of BNP, 
BNP-32 and proBNP-108, were present in plasma from control subjects and 
patients with atrial fibrillation and heart failure, suggesting that a significant 
percentage of proBNP-108 is secreted from the heart without processing.  
 
Comparison of plasma ProBNP/total BNP ratio of ventricular overload with 
that of atrial overload 
Next, we measured plasma BNP-32 and proBNP-108 in patients with heart 
failure with atrial overload and heart failure with ventricular overload. Heart 
failure with atrial overload included mitral stenosis, mitral regurgitation, and 
atrial septal defect, whereas heart failure with ventricular overload included aortic 
regurgitation and aortic stenosis. We compared the ratio of proBNP-108/total 
BNP in heart failure with atrial overload to that in heart failure with ventricular 
overload. Two peaks of IR-BNP were observed in both groups. Interestingly, 
IR-BNP-32 peak was more dominant than IR-proBNP-108 peak in heart failure 
with atrial overload; in contrast, IR-proBNP-108 and IR-BNP-32 peaks were 
nearly equivalent in heart failure with ventricular overload. As a result, the mean 
proBNP-108/total BNP ratio was higher in heart failure with ventricular overload 
than that in heart failure with atrial overload (Figure 2-A). These results suggest 
that ventricular overload alters processing of proBNP-108 (13).   
 
Tissue concentrations of proBNP and BNP-32 in ventricle and atrium 
To elucidate the mechanism for the higher proBNP-108/total BNP ratio in 



































































ventricular and atrial tissues. Resected samples of left atrial tissues and left 
ventricles were frozen in liquid nitrogen, and stored at -80°C. The atrial and 
ventricular tissues were boiled in 10 volumes of 1 mol/L acetic acid to inhibit the 
endogenous peptidase activity (14). The tissues were homogenized, centrifuged, 
lyophilized, and subjected to gel filtration HPLC on a TSK gel G2000SWXL 
column as described above for plasma. Then, each fraction was submitted to the 
FIA for BNP-32 similar to the plasma samples. Two IR-BNP peaks corresponding 
to BNP-32 and proBNP-108 were also observed in atrial and ventricular tissue. 
Interestingly, in atrial tissue, the low MW IR-BNP peak corresponding to BNP-32 
was a dominant molecular form of IR-BNP; in contrast, the high MW IR-BNP 
peak, corresponding to proBNP-108 was a dominant molecular form in 
ventricular tissue. Consequently, the mean proBNP-108/total BNP ratio was 
much higher in ventricular tissue than in atrial tissue (Figure 2-B).  
There were few studies, which measured molecular forms of BNP in 
cardiac tissue. A previous study showed that two molecular forms of IR-BNP of 
MW 4K and MW 13-15K were present in human atrial tissue (15), which is 
consistent with the present results. However, to our best of knowledge, no study 
has previously examined the molecular form of BNP in human ventricular tissue. 
Although the exact meaning of dominant presence of proBNP-108 in ventricular 
tissue remains unknown at present, these results suggest that alteration of proBNP 
processing may occur when some stress is loaded onto ventricle. 
 
Pericardial fluid concentrations of IR-BNP-32 and IR-proBNP-108 in 
patients with heart failure  
          To confirm the molecular form of BNP produced and secreted from the 
ventricular tissue, we characterized IR-BNP-32 and IR-proBNP-108 in 
pericardial fluid and plasma in patients who underwent cardiac surgery. Two 
IR-BNP peaks corresponding to BNP-32 and proBNP-108 in plasma and 



































































were present. In plasma, IR-BNP-32 was a dominant molecular form in patients 
with mitral regurgitation, while IR-proBNP-108 was a dominant molecular form 
in patients with aortic stenosis; however, IR-proBNP-108 was exclusively the 
dominant molecular form in pericardial fluid in both cases. Consequently, the 
mean proBNP-108/total BNP ratio was greater in pericardial fluid than in the 
plasma (Figure 2-C).  
           Pericardial fluid is known to contain abundant levels of various bioactive 
substances produced in the heart (16,17) and its composition is known to be close 
to the interstitial fluid in the ventricle (18). In addition, the concentrations of 
bioactive substances, such as adrenomedullin, BNP, ANP, basic fibroblast growth 
factor, and vascular endothelial growth factor, have been reported to be higher in 
pericardial fluid than in plasma (16-19). Most IR-BNP was present as 
IR-proBNP-108, irrespective of the type of heart failure. These results support the 
hypothesis again that proBNP-108 is the major molecular form of BNP in the 
ventricle and that most of proBNP-108 is secreted from ventricle without 
proteolytic processing.  
 
The post-treatment or natural course of plasma concentrations of 
IR-BNP-32 and IR-proBNP-108 in patients with heart failure  
To investigate whether the pathophysiological status of heart failure affects 
the molecular form of BNP in plasma, plasma proBNP-108 and BNP-32 levels 
were measured in patients with heart failure before and after their symptom had 
improved in response to treatments. These peptides levels were also measured in 
patients with heart failure before and after their symptom had deteriorated. 
Elevated plasma IR-BNP levels decreased after the treatments, accompanied by a 
reduction in the proBNP-108/total BNP ratio. In the cases that heart failure 
deteriorated during the observation, IR-BNP levels increased concomitantly with 
an increase in the proBNP-108/total BNP ratio.  



































































depending on the pathophysiological status of heart failure. An increased 
proBNP-108/total BNP ratio in severe heart failure may be explained in part by 
the increased production and secretion of proBNP-108 from the ventricle. 
Another possibility is that gene expression of proteolytic processing enzyme is 
not increased in parallel with the increase in gene expression of BNP precursor in 
severe heart failure, which results in the reduced proteolytic conversion of 
proBNP-108 into BNP-32.  
 
The pathophysiological significance of increased proBNP in heart failure 
          In vitro studies have shown remarkably reduced cGMP producing ability of 
proBNP-108 in vascular smooth muscle and endothelial cells compared with that 
of BNP-32 [11]. The plasma cGMP level is increased in proportion to the severity 
of mild to moderate HF, and levels of plasma cGMP correlates with those of 
plasma BNP. However, increased cGMP levels are attenuated in severe heart 
failure [20], of which mechanism has not been fully elucidated. A definite 
increase in the amount of less hormonally active proBNP-108 observed in severe 
heart failure might explain this phenomenon. Indeed, the proBNP-108/BNP-32 
ratio is increased in decompensated heart failure and that medical therapy for such 
patients decreases plasma BNP and patients’ symptoms in concert with a 
reduction in the proBNP-108/BNP-32 ratio [13]. Therefore, elucidation of the 
mechanism underlying the increased ratio of proBNP-108/BNP-32 should help to 
clarify the pathogenesis of heart failure and/or pave the way towards novel 
therapies. 
 
The mechanism of proBNP secretion without processing: new hypothesis of 
processing of proBNP 
          Like the increasing levels of proBNP-108, BNP-32 and NT-proBNP-76 in 
heart failure, proBNP-108 is also O-glycosylated according to heart failure 



































































glycosylation is a matter of obvious importance.  
        Pressure overload, volume overload, ischemia and other conditions stimulate 
BNP gene transcription. The BNP mRNA is translated in the endoplasmic 
reticulum to produce preproBNP. Removal of its signal peptide generates 
proBNP-108 that can be posttranslationally glycosylated to varying degrees at 
several sites (Ser36, Thr37, Thr44, Thr48, Thr53, Ser58, and Thr71) of its 
N-terminal region throughout the Golgi network [22]. O-glycosylated (glyco-) 
proBNP-108 is transported to the trans-Golgi network, where it is cleaved to 
BNP-32 and NT-proBNP-76 probably by furin [22,23]. Both BNP-32 and 
NT-proBNP-76 are thought to be secreted via a constitutive pathway without 
storing in secretory granules (Figure 3). 
         Levels of glyco-proBNP-108, but not of proBNP-108, are increased in the 
plasma of patients with severe heart failure [24,25]. Western blot analyses have 
revealed the presence of high MW (20-22 K) IR-BNP and low MW (4 K) IR-BNP 
species in the plasma of such patients. Digestion with deglycosylation enzymes 
for 8 h reduced the 20-22K BNP species to about 12K, which is the predicted size 
of pro-BNP-108, whereas the 4K form, corresponding to BNP-32, remained 
unchanged [11]. Thus, glyco-proBNP-108 definitely circulates in the plasma of 
patients with heart failure and is a major molecular form of proBNP.  
          How glyco-proBNP-108 is secreted without processing under conditions of 
severe heart failure is not fully understood. A recent study has shown that 
O-glycosylation at Thr71 in a region close to the cleavage site impairs 
proBNP-108 processing by furin in HEK293 cell, a specific cell line originally 
derived from human embryonic kidney cells [22,23] (Figure 3). Since the effect of 
O-glycosylation was only evaluated with furin in that vitro study, the roles of 
other possible processing enzymes, such as corin, remains unclear. It has not been 
examined whether this finding is also valid in the in the cardiac myocytes of 
atrium and ventricle in vitro, either. Therefore, further studies using cardiac 



































































processing and the effect of O-glycosylation.   
 
Conclusion 
           We review the recent studies regarding complex molecular forms of BNP, 
in plasma and tissue, primarily based on our recent results. The presence of 
proBNP-108 in plasma in patients with heart failure has almost been established. 
Recent studies also showed that the proBNP/total BNP ratio increases in 
association with pathophysiological conditions such as ventricular overload. An 
interesting hypothesis that O-glycosylation at Thr71 in a region close to the 
cleavage site impairs proBNP-108 processing by furin is proposed based on the 
experiments in HEK293 cell (Figure 3). Whether this hypothesis is true in cardiac 
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Figure 1: ProBNP-108/total BNP ratios in plasma in the control, atrial 
fibrillation and heart failure.  
(A, B) Gel filtration HPLC profile of the venous plasma extracts from control (A) 
and heart failure (B). Two peaks of high MW and low MW IR-BNPs 
corresponding to proBNP-108 and BNP-32 were observed. (C) The 
proBNP-108/total BNP ratios in plasma in the control, atrial fibrillation (Af) and 
heart failure (HF). (modified Ref. 13) 
 
Figure 2: ProBNP-108/total BNP ratios in plasma in heart failure patients 
with atrial overload and ventricular overload, cardiac tissue, and pericardial 
fluid 
 (A) The proBNP-108/total BNP ratio in heart failure patients with atrial overload 
and those with ventricular overload. (B) The proBNP-108/total BNP ratio in the 
atrial and ventricular tissue in patients with heart failure who underwent cardiac 
surgery. (C) The proBNP-108/total BNP ratios in pericardial fluid and plasma 
from the same patients who underwent cardiac surgery. (modified Ref. 13) 
 
Figure 3. Schematic representation of processing and glycosylation of 
proBNP in cardiomyocytes. 
Some of the biosynthesized proBNP-108 is O-glycosylated in Golgi apparatus. 
ProBNP-108 is converted into BNP-32 and NT-proBNP-76 by processing 
enzyme in trans-Golgi network, if O-glycosylation does not occur at Thr71. Then, 
BNP-32 and NT-proBNP-76 is secreted in an equimolar fashion via a constitutive 
pathway. If proBNP is O-glycosylated at Thr71 and is not cleaved by processing 
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